A Single-centre, Open-label, Randomized, Single-dose, 6-way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 6 Different Formulations of SB-649868 30 mg (Part A) and the Effect of Food on the Selected Formulation of SB-649868 Pharmacokinetic (Part B) in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs GSK 649868 (Primary)
- Indications Sleep disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Jun 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
- 11 Jul 2007 New trial record.